Background: Inflammation and oxidative stress play important roles in the pathogenesis and progression of chronic kidney disease (CKD) and in its complications, in particular cardiovascular disease, a major cause of death among patients undergoing dialysis treatment. We recently described that Glutaredoxin1 (Grx), an intracellular antioxidant, catalyzes oxidoreductase reactions also extracellularly, and that serum Grx levels correlate to disease severity in type 2 diabetes. Aim: In the current study we assess Grx as a potential clinical marker of oxidative stress in CKD. Methods: We examined Grx activity in 25 patients with different stages of chronic kidney failure, 19 control subjects, and 36 patients at initiation of dialysis and after 2 years of dialysis. Results: We found that Grx activity was significantly higher in CKD patients compared to control subjects, indicating an oxidized extracellular environment in CKD. Grx levels correlated to interleukin-6 and pentosidine, but not to age or GFR. In dialysis patients with Grx sampling before dialysis start and after 2 years of dialysis, Grx levels increased more in hemodialysis (HD) patients than in peritoneal dialysis patients, indicating an increased oxidative stress imbalance in HD patients. Patients who experienced a stroke or myocardial infarction at any time had a significantly higher increase in Grx during the 2 years of dialysis, compared to patients without stroke or myocardial infarction, indicating a possible association between high Grx levels and a cardiovascular event. Conclusion: Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.
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Introduction
Acute and chronic kidney failure are associated with enhanced reactive oxygen species generation and impaired antioxidant defenses [1, 2] , starting already at early stages of chronic kidney disease (CKD) and increasing with as well as contributes to disease progression [3] [4] [5] . Several intracellular redox enzymes have been measured in red blood cells in kidney failure [6] , and lipid peroxidation markers, glycation end products including pentosidine [7, 8] as well as 8-hydroxy-2'doxyguanosine (8-OH-dG) [9] have been assessed as markers of oxidative stress and inflammation in CKD, however, as of yet, there is no simple method of measuring redox balance, suitable for a point of care setting. Glutaredoxin1 (Grx) is an intracellular redox protein catalyzing glutathione dependent disulfide oxidation reduction reactions, controlling the balance between oxidized and reduced glutathione [10] . Our group recently described that serum Grx is redox active, elevated in patients with impaired fasting glucose or upon glucose overload, and decreases in diabetes patients upon antioxidant Coenzyme Q10 treatment [11, 12] . In this study, we assess for the first time serum Grx in patients with CKD compared to controls, and in CKD patients before and after 2 years of dialysis, and show that Grx is a possible marker of the degree of oxidative stress in CKD.
Materials and Methods

Patients and Control Subjects
A total of 25 CKD 3-4 patients (determined in 23 by iohexol clearance 15-59 mL/min and in 2 by CKD epi), and 36 CKD 5 patients just before entering dialysis, were included in the study. In the 36 dialysis patients, a second sample was obtained in all patients after 2 years of dialysis. The patients were grouped according to the KDIGO CKD grading [13] ; CKD3 (glomerular filtration rate [GFR] 30-60 mL/ min*1.73 m 2 , n = 12, CKD 4 (15-29 mL/min*1.73 m 2 , n = 12, and CKD5 (< 15 mL/min*1.73 m 2 , n = 37). The patients were included in the study from 2002 to 2011, and end of follow up was set to January 31, 2018. During the follow up, we recorded cardiovascular events of ischemic or hemorrhagic stroke and acute myocardial infarction.
In addition, 19 population-based control subjects were enrolled in the study. The control group consisted of individuals from the Stockholm region who were randomly selected by Statistics Sweden (a government agency) to match the patient group with regard to age and gender, and who accepted to participate, as volunteers, in the study. The population-based controls were included in the study between 2002 and 2010.
Statement of Ethics
The study protocol was approved by the Stockholm Regional Ethics Committee (Dnr 2013/2104-32, 2007/1663-31/4 and 40/02 2002). Oral and written informed consent was obtained from each patient and control subject. The study was conducted in accordance with the WMA Declaration of Helsinki.
Biochemical Assessments
Biochemical analyses of high-sensitivity C-reactive protein (hsCRP; coefficient of variation, CV, 5%), plasma cholesterol, triglycerides, high-density lipoprotein (HDL)-cholesterol, hemoglobin, creatinine, albumin (CV 3-4%) were performed at the Clinical Chemical Laboratory of Karolinska University Hospital, Stockholm, Sweden. Interleukin-6 (IL-6; CV 4%) was analyzed by immunometric assays on an Immulite 1000 Analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA, USA) using commercial kits. Plasma pentosidine was analyzed by reverse phase high performance liquid chromatography as previously described [8] .
Serum 8-OHdG levels were measured with a commercial competitive enzyme-linked immunosorbent assay kit (Japan Institute for the Control of Aging, Shizuoka, Japan), according to the manufacturer's instructions.
GFR was determined by iohexol clearance in 17 controls and 23 patients with moderate kidney failure. In the 36 patients who were included at start of dialysis, as well as in 2 controls and 2 patients with moderate kidney failure where iohexol clearance was missing, estimated GFR was determined using the CKD epi method [14] . Body mass index was calculated as weight in kilograms divided by the square of height in centimeters.
Grx Activity Assay
Grx activity in serum was determined in 96-well plates with Fluorescent Grx activity assay, using the method described by Coppo et al. [15] and previously applied in clinical samples by our group [11, 12] . In brief, reduced glutathione (GSH) reduces Grx by reactions catalyzed by glutathione reductase (GR) with electrons from NADPH. The Grx activity assay reactions where dithiol Grx reduces BSA, glutathionylated with fluorescence-labeled-GSH (BSA-S-SG-E), emitting high fluorescence upon reduction. For the Grx activity assay, 20 µL of plasma/serum was mixed thoroughly with 70 µL of 100 mM Potassium phosphate buffer, pH 7.5, containing 1 mM EDTA, 0.5 mM GSH, 0.25 mM NADPH, 50 nM baker yeast and GR in a 96-well plate. Then 10 µL of fluorescent albumin (BSA-S-SG-E) was added to each well to initiate the reaction. In addition, the reaction solutions containing serum but not GSH, NADPH, or GR were used as background. The emission at 540 nm was recorded after 520 nm excitation using a VICTOR 3 Multilabel Plate Reader (PerkinElmer, USA). Grx activity was determined by measuring the initial reaction velocity from a linear fluorescence increase. Varied concentrations of recombinant hGrx1 (IMCO Corporation Ldt AB, Stockholm, Sweden) were used to make standard curves. Then the corresponding Grx activity was calculated based on this standard curve and results given as Grx ng/mL serum. All samples were analyzed in technical triplicates.
Statistical Analysis
Data are expressed as mean and S.D. median. The differences between groups were compared with Mann-Whitney U test assuming non-Gaussian distribution of samples. Differences were considered to be significant if p < 0.05. For correlation, non-Gaussian distribution of samples was assumed and nonparametric univariate Spearman Rank correlation coefficient was used, with sig- nificance set to p < 0.05. As the number of patients and control subjects was small, we cautiously did not use multivariate analysis, and we assumed non-Gaussian distribution of samples throughout, even if some sample subsets showed normal distribution. All statistical analyses were performed using statistical software SAS version 9.4 (SAS Campus Drive, Cary, NC, USA), graphs were made in GraphPad Prism (version 7.03, San Diego, CA, USA) and some statistics calculated in GraphPad software.
Results
Clinical Characterization of Patients
Clinical and biochemical characteristics of the study population at initial sampling are summarized in Table 1 . Sixteen patients (20%) of the study population had diabetes mellitus and 23 (37%) of the patients were treated with Statins. Patients were included from 2002 to 2011 (controls 2002-2010) and followed until censor date January 31, 2018. The mean follow-up time for controls was 12.4 years, CKD3-4 (including 1 CKD 5 patient) 10.7 years, and for CKD5 patients entering dialysis, the median follow-up from initial sample at dialysis start was 7.1 years. During follow-up, we registered cardiovascular events of ischemic or hemorrhagic stroke, and acute myocardial infarction, death and if the patients underwent kidney transplantation. However, we did not censor patients at the time of transplantation. Seven patients experienced cardiovascular events in the CKD3-4 group and 15 in the dialysis group.
In total, 8 patients in the CKD3-4 group and 23 patients in the dialysis group died during follow-up. During followup, a total of 17 patients underwent kidney transplant, 6 in the CKD3-4 group and 11 patients in the dialysis group. In the control group, there were 3 cardiovascular events in 2 patients and 3 patients died during follow-up.
We first assessed Grx levels in controls compared to CKD (Fig. 1a) , and found a significantly higher Grx activity in moderate kidney failure patients (CKD3, median 20.9 ng/mL serum, range 10-29.3) compared to control subjects (median 16.4 ng/mL serum, range 9.1-22.9, p < 0.05). CKD3 and 4 had similar Grx levels as CKD5 (median 20.4 ng/mL serum, range 14.6-25.8 compared to 19.9 ng/mL range 11.6-24.1). No gender differences were detected.
When assessing Grx levels according to the presence of diabetes (median 19.2 ng/mL serum range 9.1-29.3) or no diabetes (median 20.3 ng/mL serum, range 16.2-24.1), there was no significant difference in Grx levels between the groups (Fig. 1b , p = 0.17); neither was there any correlation between HbA1c and Grx (Fig. 2a) .
We also assessed the correlation of Grx to GFR, creatinine, urea and age, and found no statistically significant correlation to these parameters (Fig. 2) . Neither was there any correlation between Grx and hsCRP; however, a clear and strong correlation to pentosidine (median 450 nmol/L, range 170-2220, n = 22) as well as IL-6 (median 4.9 pg/ mL, range 0.3-27.6), despite only 22 and 53 of 80 patients had been tested for these 2 parameters. There was also a correlation, however non-significant, to 8-OH-dG (median 0.49 ng/mL, range 0.01-1.2, n = 30; Fig. 2 ). At dialysis initiation, patients with diabetes mellitus tended to have higher Grx levels; however, the difference was not significant (p = 0.11, n = 36, results not shown). Surprisingly, when assessing the impact of the modality of dialysis during follow-up, that is, hemodialysis (HD, n = 22) or peritoneal dialysis (PD, n = 14), the PD patients' Grx levels were relatively unchanged between 0 1 . a Grx levels in CKD3 (n = 12) were significantly increased compared to control subject (n = 19). However, Grx did not further increase in CKD4 or CKD5. Lines show mean and SD, (b) there was no difference in Grx levels between patients with diabetes mellitus (n = 17) and non-diabetes subjects (n = 63). and 2 years of dialysis, whereas Grx levels had increased significantly in HD patients after 2 years of dialysis compared to dialysis initiation (Fig. 3a) . When comparing the degree of change in Grx during the 2 years, there was a significant increase in the Grx in the HD patients compared to the PD patients (Fig. 3b) . This change could not be attributed to dialysis efficiency. Kt/V at dialysis start was median 1.4 (range 1.1-2.3) in HD and 2.1 (range 1.3-3.0) for PD patients, and Kt/V at 2 years of dialysis was median 1.5 (range 1.2-2.0) for HD and median 1.9 (range 1.7-2.4) in PD. Thus, dialysis efficiency was comparable between the groups.
We then compared the difference in Grx at 2 years of dialysis compared to the time of dialysis initiation to assess whether an increase in Grx was associated with death or occurrence of a cardiovascular event (ischemic or hemorrhagic stroke or acute myocardial infarction). For this analysis, patients that underwent kidney transplant (n = 11) were censored, leaving 25 patients in the analysis. Of these, only 4 were alive at the end of follow-up, and 21 had died during follow-up. However, despite this limited number, the difference in Grx was borderline significant, median Grx difference in live patients Grx -0.65, n = 4, and dead patients Grx 2.7, n = 21, p = 0.12 results not shown. Comparing patients who were never affected by myocardial infarction or stroke (n = 9), to patients who had an event before, during or after the study (n = 16), there was a significantly higher increase in Grx in patients affected by an Comparison between Grx during dialysis in non-transplanted patients who were affected by a myocardial infarction or stroke ever (n = 16) with patients that never had such an event, showing that there was a significant increase in Grx in the group that were affected by an event; however, patients not affected by an event had an unchanged, stable Grx. b When comparing patients without event (n = 9) to patients who were affected by an event during or after study onset (n = 10), there was a tendency to higher increase in patients with future events (p = 0.052). y, years. Fig. 3 . a There was no difference between initial and 2 year Grx levels in the PD patient group; however, in the HD group, all patients increased in Grx over time and at 2 years, Grx was statistically increased compared to the levels at dialysis start. b When comparing the difference between 2 year Grx and initial Grx levels in each individual patient, the HD patient had increased in Grx significantly more than the PD patients, of which most were stable during the 2-year dialysis period. y, years.
DOI: 10.1159/000492500 event, median Grx increase 2.75 ng/mL compared to -1.1 ng/mL in patients not affected by an event, p < 0.1 (results not shown). In addition, when comparing Grx levels at 2 years with 0 years in the group with those affected by an event, there is a significant increase in Grx levels (median 19.25 at 0 years and 23.15 at 2 years, p < 0.01), Figure 4a , whereas no increase is seen in the group with no cardiovascular event (median 20.9 and 20.6 ng/mL, ns; Fig. 4a) . We then compared patients who did not suffer from a myocardial infarction or stroke prior to, during or after the study to patients who suffered from an event during or after the study period (n = 10). This is perhaps the most interesting comparison to make to assess if Grx may be predictive of an event. The Grx difference between 2 years and 0 years was median Grx decrease (-1.1 ng/mL) in the group with no event, and median increase with 1.85 ng/mL in the group that suffered an event, p = ns. When assessing the Grx difference in the group with an event during or after the 2 year study, median Grx at 2 years was 23.15 ng/mL and at 0 years 20.0, p = 0.052, indicating that in this group, although very small, n = 10, there is a clear tendency to increased Grx in the patients who will be affected by an event in the future (Fig. 4b ).
Discussion
Oxidative stress is an important culprit in the pathogenesis [1, 2] and progression [3] [4] [5] of CKD, but also in cardiovascular disease, a major complication of CKD and the major cause of death among patients undergoing dialysis treatment [16] , as well as in diabetes mellitus, 1 important cause of CKD, in which it is well established that the intracellular environment is oxidized [1, 17] . Importantly, CKD affects red blood cell and platelets that are activated and produce reactive oxygen species, which in turn activates intracellular redox enzymes, for example, superoxide dismutase, catalase, glutathione peroxidase, transferases, and glutathione reductase [6] , showing and increased redox imbalance in platelets and red blood cells of CKD patients [5, 6, [18] [19] [20] [21] . Markers of protein and lipid peroxidation, for example, malondialdehyde (MDA/TBARS), advanced glycation end products including pentosidine [7, 8] , advanced oxidation protein products [1, 5] are also altered in CKD; however, to date, there are no redox markers that are readily used in the point-of-care testing.
Our group has previously shown that diabetes patients have higher levels of the major intracellular redox protein Grx, controlling the oxidation/reduction balance of electron donor glutathione, than healthy control subjects, and that glucose overload increases Grx [11] , indicating that Grx may be a sensitive marker of oxidative stress. It has also been shown that the upregulation of Grx hampers revascularization after limb ischemia [22] , indicating that high levels of Grx may contribute to atherosclerosis and other organ damage.
In the current study, we showed that Grx was significantly increased in CKD patients compared to age matched controls. Grx was significantly increased already in patients with moderate degree of kidney failure, CKD3, and did not further increase between CKD3 and CKD5, even though earlier studies have demonstrated that the redox imbalance is further aggravated as CKD progresses. We acknowledge that the sample size in our study is small, and it is likely that several factors contribute to Grx levels, among these the underlying cause of CKD in each patient, presence or not of diabetes, medication, and other. Here, prospective consecutive longitudinal sampling of the same patient over the course of progression of CKD, in a larger number of patients, is needed to understand whether Grx indeed increases as CKD deteriorates. The same pattern of no further increase despite CKD progression, has however been found even for some other clinical redox markers of CKD [4] .
We assessed the correlation of Grx levels to known markers of kidney function, inflammation and oxidative stress in our cohort, and found a strong correlation pentosidine and IL-6, and a correlation that was not statistically significant, to 8-OH-dG. There was however no linear correlation to kidney function parameters, hsCRP, age or HbA1c. We have previously shown that extracellular Grx levels are proportional to intracellular Grx and redox state [12] ; thus, Grx may be a novel marker reflecting the overall degree of intracellular oxidative stress, clearly distinct from GFR and seemingly not largely influenced by age. Additionally, although we previously demonstrated significantly increased Grx in diabetic patients compared to healthy controls, there was no correlation between Grx and HbA1c in the current study. This however may be explained by generally lower HbA1c in CKD due to shortened erythrocyte survival, which varies significantly between patients, thus making HbA1c an unreliable marker of diabetes control in patients with concomitant CKD [23] .
Pentosidine has recently been shown by our group to be associated with oxidative stress and inflammation, low GFR, and to be an independent predictor of mortality in CKD patients [7] . Here, we demonstrate a strong significant correlation of pentosidine and the novel oxidative stress marker Grx, in spite of the fact that pentosidine levels had only been measured in 22 of our 80 subjects. Whether measuring Grx and pentosidine together adds power to predict mortality remains to be assessed in a larger prospective patient cohort. When assessing the change in each individual patient from dialysis start to 2 year follow-up, the difference in Grx was significantly larger in the HD group compared to that in the PD group, consistent with several reports in the literature of the negative influence of HD on redox balance [24, 25] , where authors described several mechanisms contributing to increased oxidative stress, including decreased glutathione redox potential. This decreased glutathione redox potential could actually be the result of impaired Grx, as Grx regulates the oxidation/reduction status of glutathione. Our current findings indicate that there may be a possible beneficial role of PD on maintaining a redox equilibrium, as Grx levels were unchanged in PD patients. Kt/V was similar in both groups, and thus the effect cannot be attributed to dialysis efficiency.
When comparing the difference in Grx at 2 years of dialysis to baseline, we censored patients who had undergone kidney transplant, leaving only 25 patients in the analysis. Of these, 4 were alive and 21 were dead; however, despite the very low number of patients, there was a clear decrease in Grx over time in patients who were alive ( -0.65 ng/mL over 2 years), whereas in patients who died, Grx difference was an increase of 2.7 ng/mL over 2 years. The difference was borderline significant despite low patient number, p = 0.12. When further comparing patients who never were affected by myocardial infarction or stroke to patients who had experienced an event, it was found that there was a significant difference between the groups with higher increase in patients affected by an event. When assessing the group that experienced an event (myocardial infarction or stroke) during or after the 2-year study period, Grx was 23.15 ng/mL at 2 years and 20.0 ng/mL at 0 years, a borderline significant increase (p = 0.052) despite the small group of only 10 patients, indicating that possibly Grx may be a predictor of cardiovascular events.
Overall, our study is clearly limited in that only a small number of patients were included, and that it is a retrospective assessment, with a considerable risk of false positive results. Thus, despite the promising features of Grx as a marker of oxidative stress and cardiovascular risk, Grx needs to be validated in a large, prospective cohort with sequential sampling over time of CKD patients. This will limit confounding factors and enable a proper multivariate analysis.
In conclusion, Grx is increased in CKD and can be used as a marker of redox balance in CKD. Grx also correlates positively to pentosidine and IL-6 levels. Our study, however, displays several limitations, as it is a small pilot study measuring a novel marker in already collected samples. In the future, a large prospective clinical study is warranted to assess Grx as a possible predictive marker for dialysis outcome and predictor of cardiovascular events during dialysis treatment.
